References
1. Lip, G.Y.H., The ABC pathway: an integrated approach to improve
AF management. Nat Rev Cardiol, 2017. 14 (11): p. 627-628.
2. Kirchhof, P., et al., 2016 ESC Guidelines for the management of
atrial fibrillation developed in collaboration with EACTS. Eur Heart J,
2016. 37 (38): p. 2893-2962.
3. Al-Khatib, S.M., et al., Rate- and rhythm-control therapies in
patients with atrial fibrillation: a systematic review. Ann Intern Med,
2014. 160 (11): p. 760-73.
4. Nikolaidou, T. and K.S. Channer, Chronic atrial fibrillation: a
systematic review of medical heart rate control management. Postgrad
Med J, 2009. 85 (1004): p. 303-12.
5. Tamariz, L.J. and E.B. Bass, Pharmacological rate control of
atrial fibrillation. Cardiol Clin, 2004. 22 (1): p. 35-45.
6. Lafuente-Lafuente, C., et al., Antiarrhythmics for maintaining
sinus rhythm after cardioversion of atrial fibrillation. Cochrane
Database Syst Rev, 2015(3): p. Cd005049.
7. Roy, D., et al., Rhythm control versus rate control for atrial
fibrillation and heart failure. N Engl J Med, 2008. 358 (25):
p. 2667-77.
8. Kirchhof, P., et al., Short-term versus long-term
antiarrhythmic drug treatment after cardioversion of atrial fibrillation
(Flec-SL): a prospective, randomised, open-label, blinded endpoint
assessment trial. Lancet, 2012. 380 (9838): p. 238-46.
9. Cosedis Nielsen, J., et al., Radiofrequency ablation as initial
therapy in paroxysmal atrial fibrillation. N Engl J Med, 2012.367 (17): p. 1587-95.
10. Wilber, D.J., et al., Comparison of antiarrhythmic drug
therapy and radiofrequency catheter ablation in patients with paroxysmal
atrial fibrillation: a randomized controlled trial. Jama, 2010.303 (4): p. 333-40.
11. Arbelo, E., et al., The atrial fibrillation ablation pilot
study: a European Survey on Methodology and results of catheter ablation
for atrial fibrillation conducted by the European Heart Rhythm
Association. Eur Heart J, 2014. 35 (22): p. 1466-78.
12. Wyse, D.G., et al., A comparison of rate control and rhythm
control in patients with atrial fibrillation. N Engl J Med, 2002.347 (23): p. 1825-33.
13. Van Gelder, I.C., et al., A comparison of rate control and
rhythm control in patients with recurrent persistent atrial
fibrillation. N Engl J Med, 2002. 347 (23): p. 1834-40.
14. Opolski, G., et al., Rate control vs rhythm control in
patients with nonvalvular persistent atrial fibrillation: the results of
the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.Chest, 2004. 126 (2): p. 476-86.
15. Chatterjee, S., et al., Pharmacologic rate versus
rhythm-control strategies in atrial fibrillation: an updated
comprehensive review and meta-analysis. Pacing Clin Electrophysiol,
2013. 36 (1): p. 122-33.
16. Van Gelder, I.C., et al., Rate control in atrial
fibrillation. Lancet, 2016. 388 (10046): p. 818-28.
17. Ionescu-Ittu, R., et al., Comparative effectiveness of rhythm
control vs rate control drug treatment effect on mortality in patients
with atrial fibrillation. Arch Intern Med, 2012. 172 (13): p.
997-1004.
18. Ogawa, S., et al., Optimal treatment strategy for patients
with paroxysmal atrial fibrillation: J-RHYTHM Study. Circ J, 2009.73 (2): p. 242-8.
19. Hohnloser, S.H., et al., Effect of dronedarone on
cardiovascular events in atrial fibrillation. N Engl J Med, 2009.360 (7): p. 668-78.
20. Potpara, T.S. and G.Y. Lip, Patterns in atrial fibrillation
management and ’real-world’ adherence to guidelines in the Balkan
Region: an overview of the Balkan-atrial fibrillation survey. Eur Heart
J, 2015. 36 (30): p. 1943-4.
21. Potpara, T.S., et al., Stroke prevention in atrial
fibrillation and ’real world’ adherence to guidelines in the Balkan
Region: The BALKAN-AF Survey. Sci Rep, 2016. 6 : p. 20432.
22. Lip, G.Y., et al., Refining clinical risk stratification for
predicting stroke and thromboembolism in atrial fibrillation using a
novel risk factor-based approach: the euro heart survey on atrial
fibrillation. Chest, 2010. 137 (2): p. 263-72.
23. Pisters, R., et al., A novel user-friendly score (HAS-BLED) to
assess 1-year risk of major bleeding in patients with atrial
fibrillation: the Euro Heart Survey. Chest, 2010. 138 (5): p.
1093-100.
24. Proietti, M., et al., Polypharmacy and major adverse events in
atrial fibrillation: observations from the AFFIRM trial. Clin Res
Cardiol, 2016. 105 (5): p. 412-20.
25. Purmah, Y., et al., Rate vs. rhythm control and adverse
outcomes among European patients with atrial fibrillation. EP Europace,
2017. 20 (2): p. 243-252.
26. Noheria, A., et al., Rhythm Control Versus Rate Control and
Clinical Outcomes in Patients With Atrial Fibrillation: Results From the
ORBIT-AF Registry. JACC Clin Electrophysiol, 2016. 2 (2): p.
221-229.
27. Camm, A.J., et al., Real-life observations of clinical
outcomes with rhythm- and rate-control therapies for atrial fibrillation
RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of
Atrial Fibrillation). J Am Coll Cardiol, 2011. 58 (5): p.
493-501.
28. Lip, G.Y., et al., Sex-related differences in presentation,
treatment, and outcome of patients with atrial fibrillation in Europe: a
report from the Euro Observational Research Programme Pilot survey on
Atrial Fibrillation. Europace, 2015. 17 (1): p. 24-31.
29. Reiffel, J.A., et al., Practice patterns among United States
cardiologists for managing adults with atrial fibrillation (from the
AFFECTS Registry). Am J Cardiol, 2010. 105 (8): p. 1122-9.
30. Nieuwlaat, R., et al., Atrial fibrillation management: a
prospective survey in ESC member countries: the Euro Heart Survey on
Atrial Fibrillation. Eur Heart J, 2005. 26 (22): p. 2422-34.
31. Kirchhof, P., et al., Management of atrial fibrillation in
seven European countries after the publication of the 2010 ESC
Guidelines on atrial fibrillation: primary results of the PREvention oF
thromboemolic events–European Registry in Atrial Fibrillation (PREFER
in AF). Europace, 2014. 16 (1): p. 6-14.
32. Chen, S., et al., Rhythm control for patients with atrial
fibrillation complicated with heart failure in the contemporary era of
catheter ablation: a stratified pooled analysis of randomized data. Eur
Heart J, 2019.
33. Nabauer, M., et al., The Registry of the German Competence
NETwork on Atrial Fibrillation: patient characteristics and initial
management. Europace, 2009. 11 (4): p. 423-34.
34. Lip, G.Y., et al., A prospective survey in European Society of
Cardiology member countries of atrial fibrillation management: baseline
results of EURObservational Research Programme Atrial Fibrillation
(EORP-AF) Pilot General Registry. Europace, 2014. 16 (3): p.
308-19.
35. Rawles, J.M., M.J. Metcalfe, and K. Jennings, Time of
occurrence, duration, and ventricular rate of paroxysmal atrial
fibrillation: the effect of digoxin. Br Heart J, 1990. 63 (4):
p. 225-7.
36. Lip, G.Y.H., et al., Prognosis and treatment of atrial
fibrillation patients by European cardiologists: One Year Follow-up of
the EURObservational Research Programme-Atrial Fibrillation General
Registry Pilot Phase (EORP-AF Pilot registry). European Heart Journal,
2014. 35 (47): p. 3365-3376.
37. Lane, D.A. and G.Y. Lip, Patient’s values and preferences for
stroke prevention in atrial fibrillation: balancing stroke and bleeding
risk with oral anticoagulation , in Thromb Haemost . 2014:
Germany. p. 381-3.
38. Proietti, M., et al., Improved Outcomes by Integrated Care of
Anticoagulated Patients with Atrial Fibrillation Using the Simple ABC
(Atrial Fibrillation Better Care) Pathway. Am J Med, 2018.131 (11): p. 1359-1366.e6.
39. Kirchhof, P., et al., Impact of the type of centre on
management of AF patients: surprising evidence for differences in
antithrombotic therapy decisions. Thromb Haemost, 2011.105 (6): p. 1010-23.
40. Jones, D.G., et al., A randomized trial to assess catheter
ablation versus rate control in the management of persistent atrial
fibrillation in heart failure. J Am Coll Cardiol, 2013.61 (18): p. 1894-903.
41. Khan, M.N., et al., Pulmonary-vein isolation for atrial
fibrillation in patients with heart failure. N Engl J Med, 2008.359 (17): p. 1778-85.
42. Fosbol, E.L., et al., Provider specialty and atrial
fibrillation treatment strategies in United States community practice:
findings from the ORBIT-AF registry. J Am Heart Assoc, 2013.2 (4): p. e000110.
43. Marrouche, N.F., et al., Catheter Ablation for Atrial
Fibrillation with Heart Failure. N Engl J Med, 2018. 378 (5):
p. 417-427.
44. Alboni, P., et al., Outpatient treatment of recent-onset
atrial fibrillation with the ”pill-in-the-pocket” approach. N Engl J
Med, 2004. 351 (23): p. 2384-91.
45. Boyd, C.M. and M. Fortin, Future of Multimorbidity Research:
How Should Understanding of Multimorbidity Inform Health System Design?Public Health Reviews, 2010. 32 (2): p. 451-474.